Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

Table 4 Overall Survival (OS) in the overall population by volume of disease

Cohorts	N. patients (%)	N. deaths (%)	OS (%) (SE)	p-value*	Median OS (months) (95% CI)	HR (95% CI)	p-value°
LV HV	244 (58.5) 173 (41.5)	98 (47.6) 108 (52.4)	27.2 (6.8) 12.6 (4.5)	0.0001	59.0 (51.0–66.9) 27.5 (22.8–32.2)	1 2.42 (1.84–3.19)	0.0001

CI confidence interval, HR hazard ratio, HV high volume, LV low volume, OS overall survival, SE standard error
^*p-value from log-rank test; °p-value from univariate Cox regression analysis

ISSN: 1479-5876